{"disease":{"id":"aml-acute-myeloid-leukemia","name":"aml acute myeloid leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07150676","title":"Harmonized Clinical and Biological Database for Integrated Research Into the Management of Pediatric Acute Myeloid Leukemia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT07425808","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":230,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT07143877","title":"Prognostic Impacts of Lipid Profile and BMI in Adult AML","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06386302","title":"Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":184,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02752035","title":"A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06073730","title":"Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"The Second Affiliated Hospital of Kunming Medical University","has_results":false},{"nct_id":"NCT07304232","title":"Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06143839","title":"VYxeoS Liposomal Italian Observational Study iN the Real Practice","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT06950034","title":"A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Solu Therapeutics, Inc","has_results":false},{"nct_id":"NCT02927262","title":"A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06648512","title":"Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)","phase":"","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Exscientia AI Limited","has_results":false},{"nct_id":"NCT06420063","title":"Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT07511829","title":"WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05092451","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07384715","title":"First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT07236931","title":"Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":71,"lead_sponsor_name":"Donghua Zhang","has_results":false},{"nct_id":"NCT05520567","title":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT04113616","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04358393","title":"A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT06158828","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06869265","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07514832","title":"VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT04749355","title":"Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"BioSight Ltd.","has_results":false},{"nct_id":"NCT04231851","title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of California, Irvine","has_results":true},{"nct_id":"NCT04722952","title":"PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06690827","title":"Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04473911","title":"Haplo Peripheral Blood Sct In GVHD Prevention","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Zachariah Michael DeFilipp","has_results":false},{"nct_id":"NCT03787498","title":"A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Opna Bio LLC","has_results":false},{"nct_id":"NCT06741722","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT07370064","title":"Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Xuzhou Medical University","has_results":false},{"nct_id":"NCT06834282","title":"CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"CERo Therapeutics Holdings, Inc.","has_results":false},{"nct_id":"NCT07342244","title":"Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Donghua Zhang","has_results":false},{"nct_id":"NCT07486713","title":"Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Rigel Pharmaceuticals","has_results":false},{"nct_id":"NCT06641648","title":"A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03730012","title":"A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT05501171","title":"Psychological Mobile App for Patients With AML","phase":"NA","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07201727","title":"CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07338357","title":"Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"First Affiliated Hospital of Guangxi Medical University","has_results":false},{"nct_id":"NCT04240002","title":"A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06835140","title":"CD123-CD16-NK Cells Immunotherapy for AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Chunji Gao","has_results":false},{"nct_id":"NCT03198234","title":"Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Roncarolo, Maria Grazia, MD","has_results":true},{"nct_id":"NCT04562792","title":"Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Children's Mercy Hospital Kansas City","has_results":true}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}